We would like to inform you that the European Medicines Agency has confirmed that the benefits of Avastin in combination with paclitaxel outweigh its risks and that this combination remains a valuable treatment option for patients suffering from metastatic breast cancer.

The Agency's Committee for Medicinal Products for Human Use (CHMP) also concluded that the balance of benefits and risks of Avastin in combination with docetaxel is negative and that this combination should no longer be used in the treatment of breast cancer. Patients who are currently being treated with this combination should discuss their ongoing treatment with their doctor.

A press release and a questions and answers document referring to this matter can be found in the following links:

http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/12/WC500099929.pdf

http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/12/WC500099939.pdf